media – Page 233 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Next-Gen Esophageal DNA Test Offers Enhanced Assay Performance and Lower Costs

Chronic heartburn may indicate Barrett’s Esophagus (BE), a precancerous condition where the esophagus lining is damaged due to digestive fluids. Although BE itself doesn’t manifest symptoms, it significantly increases the risk of developing esophageal adenocarcinoma (EAC), a dangerous cancer. Many individuals with BE are unaware of their condition and consequently, their elevated cancer risk. Timely identification of BE and precancerous cells is crucial for effective monitoring and intervention, preventing the progression to fatal esophageal cancer. Now, an advanced test for detecting esophageal precancer has demonstrated improved assay efficiency and cost-effectiveness in comprehensive validation studies. Lucid Diagnostics (New York, NY, USA) has launched EsoGuard 2.0, its next-generation EsoGuard Esophageal DNA test. The EsoGuard test begins with extracting DNA from esophageal cells gathered using the EsoCheck Cell Collection Device. This DNA undergoes bisulfite conversion, tagging unmethylated sites. It then focuses on two genes, VIM and CCNA1, identifying 31 methylation sites linked to ...
- Source: drugdu
- 87
- December 16, 2023
Blood Tests Used to Hunt for Cancer DNA May Help Detect Cancers Faster

For a long time, visible signs of tumor growth on scans were the benchmark for initiating cancer treatment. However, the emergence of precision oncology tools, including circulating tumor DNA sequencing, is changing this approach. These advancements allow for earlier cancer detection and adaptation of treatment strategies to combat mutations that cause resistance to current therapies. They also offer the potential for less toxic alternatives to chemotherapy. New research led by a clinical scientist at UC Davis Health (Sacramento, CA, USA) highlights the benefits of using blood tests to search for cancer DNA. This method can speed up cancer detection and inform the use of targeted treatments. Cancer DNA circulating in a patient’s blood can be identified from a simple blood draw. This DNA is then sequenced to determine its genetic structure, helping to classify the cancer based on the findings in the blood sample. Unlike traditional tissue biopsies, which are ...
- Source: drugdu
- 88
- December 16, 2023
Nuzyra ® has been on the market for two years and both dosage forms have been included in medical insurance

On December 13, 2023, the National Health Insurance Bureau and the Ministry of Human Resources and Social Security announced the “National Drug List for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2023)”, and the oral dosage form of Nuzyra ® (omadacycline mesylate), exclusively promoted by HanHui Pharma (a wholly owned subsidiary of HaiZheng Pharmaceuticals) in mainland China and the product of Zaidin Pharmaceuticals, has successfully been included in the 2023 edition of the National Health Insurance The oral dosage form of Nuzyra ® (omadacycline mesylate), a product of Zaidin Pharmaceuticals, has been successfully included in the 2023 edition of the National Health Insurance Drug Catalog, which will be formally implemented on January 1, 2024 Mr. Shen Xinghu, Secretary of the Party Committee and Chairman of the Board of Directors of Haizheng Pharmaceutical, said: Haizheng Pharmaceutical is committed to building HANHUI into an industry-leading pharmaceutical enterprise integrating research, production ...
- Source: drugdu
- 87
- December 16, 2023
First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Ipilimumab Biosimilar HLX13

Shanghai, China, Dec 13th, 2023 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first subject was dosed for a phase 1 clinical trial of the company’s independently developed ipilimumab biosimilar HLX13 (recombinant anti-CTLA-4 fully human monoclonal antibody injection) in China. Immune checkpoint inhibitors are playing a crucial part in immunotherapy, which has emerged in recent years as a novel approach to combating tumour cells with distinct advantages and enormous promise [1]. In addition to PD-1/L1 and LAG-3, CTLA-4 is also an inhibitory immune checkpoint which expressed on regulatory T cells and activated T cells and has a higher affinity to B7 molecules compared with CD28, thus can competitively bind to B7 molecules to inhibit the proliferation and activation of T cells [2]. Anti-CTLA-4 fully human monoclonal antibody (mAb) can block the inhibitory effects of CTLA-4 on the co-stimulation signal necessary to T cell activation and can increase the number ...
- Source: drugdu
- 125
- December 16, 2023
New Sample Preparation Solutions Simplify and Automate Respiratory Diagnostic Testing

Clinical laboratories performing respiratory testing are required to generate results of the highest quality results. Now, an automated nucleic acid purification instrument along with kits for the isolation and purification of viral and bacterial pathogens from respiratory biological specimens has been designed to fulfill the requirements of these laboratories. Thermo Fisher Scientific Inc. (Waltham, MA; USA) has launched the high-throughput, versatile KingFisher Apex Dx system that allows scientists’ labs to recover quality nucleic acids for sensitive downstream applications with maximum consistency, reproducibility, and reliability. The system has been designed to be a part of modular sample preparation for real-time PCR analysis workflow, providing precise results, accurate data management, and robust security features that meet cybersecurity and diagnostic regulatory standards. Additionally, Thermo Fisher has launched the MagMAX Dx Viral/Pathogen NA Isolation kit which offers advanced formulation to ensure reproducible results and is automation-compatible with the KingFisher Apex Dx. These products together ...
- Source: drugdu
- 111
- December 15, 2023
Glycan analysis holds promise for early diagnosis of various cancers

In the future, a little saliva may be enough to detect an incipient cancer. Researchers at the University of Gothenburg have developed an effective way to interpret the changes in sugar molecules that occur in cancer cells. Glycans are a type of sugar molecule structures that is linked to the proteins in our cells. The structure of the glycan determines the function of the protein. It has been known for a while that changes in glycan structure can indicate inflammation or disease in the body. Now, researchers at the University of Gothenburg have developed a way to distinguish different types of structural changes, which may provide a precise answer to what will change for a specific disease. “We have analyzed data from about 220 patients with 11 differently diagnosed cancers and have identified differences in the substructure of the glycan depending on the type of cancer. By letting our newly ...
- Source: drugdu
- 102
- December 15, 2023
MAPS Seeks Approval of First Psychedelic-Assisted Therapy for PTSD

Pharmaceutical Executive Editorial Staff MAPS Public Benefit Corporation filed a new drug application for MDMA (midomafetamine capsules) for use with psychological intervention for the treatment of post-traumatic stress disorder. MAPS Public Benefit Corporation has submitted a new drug application (NDA) to the FDA in what would represent the first approved psychedelic treatment for post-traumatic stress disorder (PTSD). MAPS is seeking approval of MDMA (midomafetamine capsules) for use with psychological intervention comprised of psychotherapy and additional supportive services provided by a qualified healthcare provider for PTSD.1 MAPS was previously granted Breakthrough Therapy Designation by the FDA for MDMA and is seeking a priority review for the NDA submission. “The filing of our NDA is the culmination of more than 30 years of clinical research, advocacy, collaboration and dedication to bring a potential new option to adults living with PTSD, a patient group that has experienced little innovation in decades,” Amy Emerson, ...
- Source: drugdu
- 102
- December 15, 2023
Sanofi Abandons Deal for Rare Disease Drug Amid FTC’s Monopoly Concerns

Sanofi, which markets the two primary treatments for Pompe disease, was trying to add a third one by licensing rights to a Maze Therapeutics drug candidate with a different therapeutic approach. A Federal Trade Commission complaint alleges the deal amounts to a monopoly player taking out its competition. By FRANK VINLUAN Sanofi is walking away from a deal to license an experimental Maze Therapeutics drug for a rare enzyme deficiency after the Federal Trade Commission challenged the transaction as anti-competitive. The French pharmaceutical giant already markets Lumizyme and Nexviazyme for the disorder, called Pompe disease. Until this year, they were the only available Pompe treatments. In an administrative complaint filed Monday, the anti-trust regulator said Sanofi’s deal for Maze’s drug candidate amounts to a large company trying to eliminate a smaller competitor. Both Sanofi and Maze disagree with the FTC’s position. South San Francisco-based Maze said it is reviewing its ...
- Source: drugdu
- 105
- December 15, 2023
Sino Biopharm’ S&P ESG Score Gains Another Boost, Stays in Top 9% Globally

Recently, S&P Global Corporate Sustainability Assessment (CSA) has been releasing the results of 2023 Environmental, Social and Governance (ESG) scores. Sino Biopharm (HK.1177) has achieved a second consecutive year of improved ratings. This year, the Group’s rating steadily improved to 55 points, up 10 points from the previous year, and ranked in the top 9% globally for the second consecutive year. The S&P Global Corporate Sustainability Assessment is one of the world’s largest annual assessments of corporate sustainability practices, which comprehensively reflects the level of ESG management and disclosure of companies through quantitative scoring of companies’ ESG management and performance, and is an important basis for investment decisions and data analysis by global investors. 2023, approximately 350 companies in the pharmaceutical industry around the world were invited to participate in the assessment. For two consecutive years, the company has outperformed 91% of its global peers, representing the organization’s high recognition ...
- Source: drugdu
- 105
- December 15, 2023
Mayor of Bogota, Colombia, Claudia Lopez and Ambassador of Colombia, Sergio Cabrera and his entourage visited SINOVAC.

On the afternoon of December 5, 2023, Claudia Lopez, Mayor of Bogota, Colombia, and Sergio Cabrera, Ambassador of Colombia to China, visited SINOVAC, accompanied by Ruth Amparo Medina, Director of International Relations of Bogota City, Oscar Felipe Rueda, Commercial Counselor of the Embassy of Colombia in China, and Daniel Mesa, First Secretary of the Embassy. Accompanied by Yin Weidong, Chairman, President and CEO of the company, Yang Guang, Chief Commercial Officer, and Gao Qiang, Chief Operating Officer. Previously, SINOVAC successfully won the bidding for the Bogotá Vaccine Plant Project (“Bogotá Project”) and entered into a strategic cooperation with the Bogotá Municipal Government, in which the two parties set up a joint venture company, BogotáBio, to promote the localized production of a variety of vaccines and new vaccines in Colombia. The joint venture, BogotáBio, will promote the local production of various vaccines in Colombia as well as the research and development ...
- Source: drugdu
- 97
- December 15, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.